SEC Comment Letter for CervoMed Inc. (CRVO) (CIK 0001053691) (CRVO) — Dec 29, 2017
CervoMed Inc. (CRVO) (CIK 0001053691)
Date: Dec. 29, 2017 · CIK: 0001053691 · Accession: 0000000000-17-045352
AI Filing Summary & Sentiment
Reasoning
Letter
December 27, 2017 David G. Kalergis Chief Executive Officer Diffusion Pharmaceuticals Inc. 1317 Carlton Avenue, Suite 200 Charlottesville, VA 22902 Diffusion Pharmaceuticals Inc. Registration Statement on Form S-1 Filed December 20, 2017 File No. 333-222203Re: Dear Mr. Kalergis: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: David S. Rosenthal, Esq.
Show Raw Text
December 27, 2017
David G. Kalergis
Chief Executive Officer
Diffusion Pharmaceuticals Inc.
1317 Carlton Avenue, Suite 200
Charlottesville, VA 22902
Diffusion Pharmaceuticals Inc.
Registration Statement on Form S-1
Filed December 20, 2017
File No. 333-222203Re:
Dear Mr. Kalergis:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: David S. Rosenthal, Esq.